Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Talibegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 15/20 | 0.55 |
| ▸ | ADRB1 known ✓ | P08588 | 7/20 | 0.55 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.55 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talibegron SCHEMBL1230810 | 1.00 | ALOX15 (1.00) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Talibegron SCHEMBL328977 | 0.99 | ALOX15 (0.97) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Talibegron SCHEMBL3699503 | 0.99 | ALOX15 (0.97) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Talibegron SCHEMBL6060362 | 0.99 | ALOX15 (0.97) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL8976435 | 0.90 | ALOX15 (0.82) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL8976317 | 0.90 | ALOX15 (0.82) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL8976468 | 0.89 | ALOX15 (0.80) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL8976161 | 0.89 | ALOX15 (0.80) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| SCHEMBL8976026 | 0.89 | ALOX15 (0.80) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| SCHEMBL8976032 | 0.89 | ALOX15 (0.80) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5480910-A | 4-(2-(2-HYDROXY-2-PHENYLETHYLAMINO)ETHOXY)PHENYLACETIC ACID OR SALT IS ADMINISTERED FOR GASTROINTESTINAL DISORDERS | ZENECA LIMITED (GB) | 1996-01-02 | — | — | US | disclosed |
| EP-0516349-B1 | 2-Hydroxy-2-phenylethylamine derivatives as beta-3-adrenoceptor agonists | ZENECA LTD (GB) | 1995-09-20 | — | — | EP | disclosed |
| US-5434184-A | B3-adrenoceptor agonist | ZENECA LIMITED (GB) | 1995-07-18 | — | — | US | disclosed |
| US-5393779-A | Anti-obesity, hypoglycemic, adrenergic blocking agents | ZENECA LIMITED (GB) | 1995-02-28 | — | — | US | disclosed |
| EP-0516349-A2 | 2-Hydroxy-2-phenylethylamine derivatives as beta-3-adrenoceptor agonists | ZENECA LIMITED (GB) | 1992-12-02 | — | — | EP | disclosed |